Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 · New England Journal of Medicine · 4,204 citations
https://doi.org/10.1056/nejmoa1809615
P
Peter Schmid
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
375
Papers
24.3K
Citations
61
h-index
148
i10-index
Peter Schmid is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Cancer Immunotherapy and Biomarkers & HER2/EGFR in Cancer Research. The author has an h-index of 61, co-authored 319 publications.
Papers by this author
worksPembrolizumab for Early Triple-Negative Breast Cancer
2020 · New England Journal of Medicine · 2,944 citations
https://doi.org/10.1056/nejmoa1910549
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
2020 · The Lancet · 1,743 citations
https://doi.org/10.1016/s0140-6736(20)32531-9
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
2019 · The Lancet Oncology · 1,172 citations
https://doi.org/10.1016/s1470-2045(19)30689-8
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
2022 · New England Journal of Medicine · 1,000 citations
https://doi.org/10.1056/nejmoa2202809
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
2018 · Annals of Oncology · 608 citations
https://doi.org/10.1093/annonc/mdy518
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat